

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information on this form unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/537,747-Conf. #4895	
			Filing Date	March 27, 2006	
			First Named Inventor	Judd M. Berman	
			Art Unit	1625	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	5	Attorney Docket Number	IPT-075

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-6,995,254	02-07-2006	Payne et al.	
	A2*	US-6,951,729	10-04-2005	Dewolf, Jr. et al.	
	A3*	US-6,821,746-A1	11-23-2004	DeVolf, Jr. et al.	
	A4*	US-6,503,903	01-07-2003	Miller et al.	
	A5*	US-6,559,172	05-06-2003	Heerding et al.	
	A6*	US-6,573,272	06-03-2003	Miller et al.	
	A7*	US-6,846,819	01-25-2005	Miller et al.	
	A8*	US-6,762,201	07-13-2004	Miller et al.	
	A9*	US-6,730,684	05-04-2004	Miller et al.	
	A10*	US-6,531,126-A1	03-11-2003	Famer	
	A11*	US-6,527,759	03-04-2003	Tachibana et al.	
	A12*	US-6,518,270	02-11-2003	Amin et al.	
	A13*	US-6,518,239	02-11-2003	Kuo et al.	
	A14*	US-6,517,827	02-11-2003	Bacon Kurtz et al.	
	A15*	US-6,461,829	10-08-2002	Kahne	
	A16*	US-6,448,054	09-10-2002	Poznansky et al.	
	A17*	US-6,423,341-A1	07-23-2002	Yamaguchi et al.	
	A18*	US-6,495,551	12-17-2002	Betts et al.	
	A19*	US-6,486,149-A1	11-26-2002	Onodera et al.	
	A20*	US-6,441,162-A1	08-27-2002	Yasui et al.	
	A21*	US-6,436,980	08-20-2002	Leger et al.	
	A22*	US-6,399,629	06-04-2002	Chamberland et al.	
	A23*	US-6,518,263	02-11-2003	Nishitani et al.	
	A24*	US-6,503,881-A1	01-07-2003	Krieger et al.	
	A25*	US-6,486,148-A1	11-26-2002	Savage et al.	
	A26*	US-6,465,429	10-15-2002	Hancock et al.	
	A27*	US-6,388,070	05-14-2002	Deshpande et al.	
	A28*	US-6,531,649	03-11-2003	Mannerloef et al.	
	A29*	US-6,531,465	03-11-2003	Ascher et al.	
	A30*	US-6,528,089	03-04-2003	Kothrade et al.	
	A31*	US-6,521,408	02-18-2003	Kawasaki et al.	
	A32*	US-6,518,487	02-11-2003	Lowe et al.	
	A33*	US-6,531,508	03-11-2003	Nomura et al.	
	A34*	US-6,514,962	02-04-2003	Shibatani et al.	
	A35*	US-6,503,953-A1	01-07-2003	Vyden	
	A36*	US-6,492,351	12-10-2002	Zhang et al.	
	A37*	US-6,461,607	10-08-2002	Famer	
	A38*	US-6,495,161	12-17-2002	Soon-Shiong et al.	
	A39*	US-6,495,158	12-17-2002	Buseman et al.	
	A40*	US-6,486,165-A1	11-26-2002	Zhang et al.	
	A41*	US-6,514,535-A1	02-04-2003	Marchant	
	A42*	US-6,489,318	12-03-2002	Copar et al.	
	A43*	US-6,497,886	12-24-2002	Breitenbach et al.	
	A44*	US-6,503,539-A1	01-07-2003	Gestrelus et al.	
Examiner Signature	/Noble Jarrell/			Date Considered	06/22/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information on unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/537,747 -Conf. #4895	
			Filing Date	March 27, 2006	
			First Named Inventor	Judd M. Berman	
			Art Unit	1625	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	5	Attorney Docket Number	IPT-075

A45*	US-6,500,459	12-31-2002	Chhabra et al.	
A46*	US-6,500,463	12-31-2002	van Lengenich	
A47*	US-6,448,238	09-10-2002	Shoichet et al.	
A48*	US-6,432,444	08-13-2002	Fischetti et al.	
A49*	US-6,333,045	12-25-2001	Yasueda et al.	
A50*	US-6,291,462	09-18-2001	Bartholomaeus et al.	
A51*	US-6,221,859	04-24-2001	Dorso et al.	
A52*	US-6,514,986-A1	02-04-2003	de Souza et al.	
A53*	US-6,340,689	01-22-2002	Dubois et al.	
A54*	US-6,309,663	10-30-2001	Patel et al.	
A55*	US-6,303,572	10-16-2001	Rowe et al.	
A56*	US-6,277,836	08-21-2001	Borody et al.	
A57*	US-6,367,985	04-09-2002	Lee et al.	
A58*	US-6,468,964	10-22-2002	Rowe et al.	
A59*	US-6,448,449-A1	09-10-2002	Larrow	
A60*	US-6,423,741	07-23-2002	Khanuja et al.	
A61*	US-6,406,880	06-18-2002	Thornlon	
A62*	US-6,395,746	05-28-2002	Cagle et al.	
A63*	US-6,346,391	02-12-2002	Oethinger et al.	
A64*	US-6,294,192	09-25-2001	Patel et al.	
A65*	US-6,267,985	07-31-2001	Chen et al.	
A66*	US-6,235,908	05-22-2001	Fey et al.	
A67*	US-6,515,113-A1	02-04-2003	Raymond et al.	
A68*	US-6,509,327	01-21-2003	Cagle et al.	
A69*	US-6,503,955	01-07-2003	Dobroszi et al.	
A70*	US-6,525,066-A1	02-25-2003	Fukumoto et al.	
A71*	US-6,531,291	03-11-2003	Kabbash et al.	
A72*	US-6,514,953	02-04-2003	Armitage et al.	
A73*	US-6,514,541-A1	02-04-2003	Khanuja et al.	
A74*	US-6,428,579	08-06-2002	Valentini	
A75*	US-6,451,339-A1	09-17-2002	Patel et al.	
A76*	US-6,503,906	01-07-2003	Lee	
A77*	US-6,133,260	10-17-2000	Matzke et al.	
A78*	US-6,174,878	01-16-2001	Gamache et al.	
A79*	US-6,184,380	02-06-2001	Chiu et al.	
A80*	US-6,187,341	02-13-2001	Johnson et al.	
A81*	US-6,194,429	02-27-2001	Gunn et al.	
A82*	US-6,194,441	02-27-2001	Roberts et al.	
A83*	US-6,198,000	03-06-2001	Hawkins	
A84*	US-6,221,864	04-24-2001	Hirayama et al.	
A85*	US-6,248,363	06-19-2001	Patel et al.	
A86*	US-6,239,113	05-29-2001	Dawson et al.	
A87*	US-6,239,141	05-29-2001	Allen et al.	
A88*	US-2006-0183908	08-17-2006	Berman, et al.	
A89*	US-4,154,943	05-15-1979	Kuehne	
A90*	US-4,977,159	12-11-1990	Sevrin et al.	
A91*	US-5,614,551	03-25-1997	Dick et al.	
Examiner Signature	/Noble Jarrell/			Date Considered
				06/22/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/537,747 -Conf. #4895	
			Filing Date	March 27, 2006	
			First Named Inventor	Judd M. Berman	
			Art Unit	1625	
			Examiner Name	Not Yet Assigned	
Sheet	3	of	5	Attorney Docket Number	IPT-075

A92*	US-5,624,941	04-29-1997	Barth et al.	
A93*	US-5,932,743	09-03-1999	Collini et al.	
A94*	US-5,985,867	11-16-1999	Rodgers et al.	
A95*	US-6,372,752	04-16-2002	Staveski et al.	
A96*	US-6,451,816	09-17-2002	Biedermann et al.	
A97*	US-6,469,046	10-22-2002	Daines et al.	
A98*	US-6,503,908	01-07-2003	Maw et al.	
A99*	US-3,828,068		Minien, P.	6 August 1974
A100*	US-6,673,941		Heerding et al	6 January 2004
A101*	US-6,765,005		Miller et al.	20 July 2004
A102*	US-6,964,970		Miller et al.	15 November 2005
A103*	US-7,048,926-A1	05-23-2006	Brandt et al.	
A104*	US-7,049,310	07-29-2004	Burgess et al.	
A105*	US-US-2005-0250810		Miller, et al.	22 September 2005
A106	US-US-2006-0142265	06-29-2006	Miller, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ¹ -Number ² -Kind Code ³ (if known)	MM-DD-YYYY			
	B1	WO-00/27628	05-18-2000	Gunter, Walter		
	B2	WO-02/10332	02-07-2002	Wustefeld, Frank		
	B3	WO-9518619	07-13-1995	Smithkline Beecham Corp et al.		
	B4	WO-9600730	01-11-1996	Smithkline Beecham Corp et al.		
	B5	WO-9748696	12-24-1997	Klinge Co Chem Pharm Fab et al.		
	B6	WO-9857952	12-23-1998	Sepracor Inc et al.		
	B7	WO-0148248	07-05-2001	Millennium Pharm Inc et al.		
	B8	WO-0126652	04-19-2001	Smithkline Beecham Corp et al.		
	B9	WO-0126654	04-19-2001	Smithkline Beecham Corp et al.		
	B10	WO-0127103	04-19-2001	Smithkline Beecham Corp et al.		
	B11	WO-0242273	05-30-2002	Squibb Bristol Myers Co et al.		
	B12	WO-0248097	06-20-2002	Corvas Int Inc et al.		
	B13	EP-0407200	01-09-1991	Kanagafuchi Chemical Ind		
	B14	HU-210679	07-28-1993	Richter Gedeon Vegyeszeti Gyar Rt.		
	B15	WO-04052890	06-24-2004	Affinium Pharmaceuticals, Inc.		
Examiner Signature	/Noble Jarrell/			Date Considered	06/22/2010	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/537,747-Conf. #4895	
			Filing Date	March 27, 2006	
			First Named Inventor	Judd M. Berman	
			Art Unit	1625	
			Examiner Name	Not Yet Assigned	
Sheet	4	of	5	Attorney Docket Number	IPT-075

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). ² See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Entry Office that issued the document, by the two-letter code (WIPO Standard 37.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C1	Bergler, Helmut, et al., "Protein EnvM is the NADH-dependent Enoyl-ACP Reductase (FabI) of Escherichia Coli," J. Biological Chemistry, Vol. 269, No. 8, 02/25/94, pp. 5493-5498.		
	C2	Grassberger, Maximilian, et al., "Preparation and Antibacterial Activities of New 1,2,3-Diazaborine Derivatives and Analogues," J. Med. Chemistry, 1984, 27, 947-953.		
	C3	Heath, Richard J., et al., "A Triclosan-Resistant Bacterial Enzyme," Nature, Vol. 406, 07/13/00, p. 145-146.		
	C4	Heath, Richard J., et al., "Regulation of Fatty Acid Elongation and Initiation by Acyl-Acyl Carrier Protein in Escherichia Coli," J. Biological Chemistry, Vol. 271, No. 4, 01/26/96, pp. 1833-1836.		
	C5	Hedc, Richard F., Organic Reactions, 1982, 27, pp. 345-390.		
	C6	Levy, Colin W., et al., "Molecular Basis of Triclosan Activity," Nature, Vol. 398, 04/01/99, pp. 383-384.		
	C7	McMurray, Laura M., et al., "Triclosan Targets Lipid Synthesis," Nature, Vol. 394, 08/04/98, pp. 531-532.		
	C8	Turnowsky, Friederike, et al., "envM Genes of Salmonella Typhimurium and Escherichia Coli," J. Bacteriology, Vol. 171, No. 12, 12/89, pp. 6555-6565.		
	C9	Ward, Walter H.J., et al., "Kinetic and Structural Characteristics of the Inhibition of Enoyl (Acyl Carrier Protein) Reductase by Triclosan," Biochemistry, 1999, Vol. 38, No. 38, pp. 12514-12525.		
	C10	Jossang-Yanagida, Akino, et al., "Tetrahydropyridoazepines and Tetrahydropyridoazepinones from the Corresponding Dihydroquinolones," J. Heterocyclic Chemistry, Vol. 15, pp. 249-251.		
	C11	Abou-Gharbia et al., "Psychotropic Agents: Synthesis and Antipsychotic Activity of Substituted B-Carbolines," J. Med. Chem., 30 (6): 1100-1115 (1987)		
	C12	Abou-Gharbia et al., "Reserpine Analogue: Synthesis of B-Carbolines Derivatives," J. Chem. Soc., pp. 3926-3929 (1963).		
	C13	Jianxiong et al., "Synthesis and Antistaphylococcal Activity of Nematophin and Its Analogs," Biorganic & Medicinal Chemistry Letters, Oxford, GB, 7(10): 1349-1352, (May 20, 1977) XP004136332		
	C14	Miller et al., "Discovery of Aminopyridine-Based Inhibitors of Bacterial Enoyl-ACP Reductase (FAB); J. Med. Chem. 2002, Vol. 45, pps. 3246-3256.		
	C15	Misztal et al., "Synthesis and Pharmacologic Properties of Pyridol Derivatives of 3-Methylaminoindole 2-Methyltryptamine and Isotryptamine," Archivum Immunologiae et Therapiae Experimentals, 24(6): 851-852 (1976).		
	C16	Pachter et al., "The Chemistry of Hortiamine and 6-Methoxyhirsutamine," J. Amer. Chem., 83:635-642 (1961)		
	C17	Rehse et al., "Dopaminanalogue 1,2,3,4-Tetrahydro-B-Carboline," Arch. Pharm., 311(1): 11-18 (1978).		
Examiner Signature	/Noble Jarrell/		Date Considered	06/22/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N/J/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information on this form unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/537,747 - Conf. #4895	
			Filing Date	March 27, 2006	
			First Named Inventor	Judd M. Berman	
			Art Unit	1625	
			Examiner Name	Not Yet Assigned	
Sheet	5	of	5	Attorney Docket Number	IPT-075

C18	Shoji et al., "Two Novel Alkaloids from Evodia Rutaecarpa," J. Natural Products, 52(5): 1160-1162 (1989).	
C19	Database CA on STN, AN 7:66733, Rosenmund et al., "Chemistry of indole II...," <i>Chem Ber.</i> 103(2): 496-509.	
C20	Database CAOLD on STN, AN CA51:10524d, Hellman et al., "N-Mannich bases (VI) condensation..." <i>Direct Submission</i> (1953).	
C21	Database CAPLUS on STN, AN 1977:439214, Misztal et al., "Synthesis and pharmacologic properties of pyridoyl..." <i>Arch Immunol Ther Exp.</i> 24(6): 851-862 (1976).	
C22	DATABASE Crossfire Beilstein, 1966, Database accession no. 2819049, 2819050, XP002216033.	
C23	Himmer et al., "Synthesis and Antibacterial In Vitro Activity of Novel Analogues of Nematophin," <i>Bioorganic & Medicinal Chemistry Letters</i> , 8(15): 2045-2050 (August 1998).	
C24	Database CAPLUS on STN, AN 1986:68547, Stuetz, et al., "Synthesis and Structure Activity..." <i>J Med Chem.</i> 29(1): 112-25, (1986).	
C25	Database CAPLUS on STN, AN 1991:428908, Fuse, et al., "Preparation of cinnamamide derivatives..." <i>EP407200A1</i> . (1991).	
C26	Database CAPLUS on STN, AN 1999; 325910 Aslanian et al., "Preparation of phenylalkylimidazoles..." <i>WO99/24406</i> . (1999).	
C27	Stutz et al., "Synthesis and Structure-Activity Relationships of Nafitine-Related Allylamine Antimicrobials," <i>Journal of Medicinal Chemistry</i> , 1996, Vol. 29, No. 1, 112-125.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

Examiner Signature	/Noble Jarrell/	Date Considered	06/22/2010
--------------------	-----------------	-----------------	------------